Leukemia Research Study
|
Lenalidomide (Revlimid) in CLL and SLL
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating an experimental treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The study drug--an immune modulator that may block blood vessel growth in cancers--may help normalize blood counts, reduce leukemia-related symptoms, decrease risk of infections and/or improve quality of life and long-term survival. Consenting subjects will take an oral dose of lenalidomide daily for 3 weeks and then no medication for 3 weeks and repeat the regimen 4 times (4 cycles). Response will be measured at 24 weeks. Responding patients will have the option to continue the regimen for 2 additional cycles (if in CR after 4 cycles) or 4 cycles (if in PR after 4 cycles).
If you have been diagnosed with CLL or SLL , have already been treated for CLL or SLL and are 21 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-402-0797 or email us atBloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Leukemia
|
If you or someone you know is diagnosed with ALL, AML, CLL, or CML, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant and T Cell Add Back to Treat Leukemia
|
If you or someone you know is diagnosed with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), or chronic myrlogenous leukemia (CML), you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant for High Risk Patients with Leukemia
|
If you have been diagnosed with ALL, AML, CLL, CML, or CMML you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Subcutaneous Rituximab (Rituxan) in Chronic Lymphocytic Leukemia (CLL)
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Chronic Lymphocytic Leukemia (CLL). The study drug, a monoclonal antibody, may help normalize blood counts, reduce leukemia related symptoms, decrease risk of infections and/or improve quality of life and long term survival. Consenting subjects will receive one intravenous infusion of study medication Rituximab (Rituxan) at the NIH Clinical Center followed by self-administered injections under the skin of the same drug 3 times a week for 12 weeks at home.
If you have been diagnosed with CLL, have already been treated with fludarabine and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Leukemia Research Study
|
WT1 +PR1 peptide vaccination for AML or CML
|
If you are 18 years old or older and have been diagnosed with AML or CML, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your leukemia. This study will test whether vaccination with a WT1 peptide and a PR1 peptide may increase the number of immune cells responding to your leukemia and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your leukemia Consenting subjects will receive one dose of WT1 vaccine and one dose of PR1 vaccine every other week for 12 weeks (total of 6 vaccinations) followed by post vaccination evaluations 2 weeks and 4 weeks after the last dose of the vaccines.
To find out if you qualify or for more information, please contact or study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
WT1 peptide vaccination study for Leukemia (AML, ALL, CML or CMML)
|
If you are 18 years old or older and have been diagnosed with AML, ALL, CML or CMML, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your leukemia. This study will test whether vaccination with a WT-1 peptide may increase the number of immune cells responding to your leukemia and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your leukemia. Consenting subjects will receive two intravenous infusion of fludarabine followed by 9 weekly vaccinations with a WT1 peptide followed by monthly follow up evaluations.
To find out if you qualify or for more information, please contact the study coordinator at 301-496-3841or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute